Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. (PHVS) received a notice that officer David Nassif intends to sell up to 6,000 shares of common stock under Rule 144. The shares, held at Morgan Stanley Smith Barney LLC, had an indicated value of $218,800.80 as of September 21, 2026, and are listed on NASDAQ. The stock to be sold is restricted stock originally acquired from the issuer on April 15, 2025, and the notice reports no other Rule 144 sales in the past three months.
Pharvaris N.V. (PHVS) director Elisabeth Bjork exercised stock options and sold the resulting shares on September 17, 2026. She exercised options for 35,000 shares at 14.3900 per share and 17,500 shares at 18.1400 per share, then sold 52,500 common shares in a cashless exercise transaction at a weighted average price of 37.8935 per share, with individual sale prices ranging from 37.62 to 38.05.
Pharvaris N.V. (PHVS) director Robert Glassman reported an option exercise and same-day sale involving 14,493 shares on September 17, 2026. He exercised stock options to acquire 14,493 shares of Common Stock at $18.14 per share and then sold 14,493 shares at a weighted average price of $38.5574 per share in a cashless exercise transaction. These transactions were carried out as a scheduled exercise and sale under a Rule 10b5-1 trading plan.
Pharvaris N.V. (PHVS) reported an insider transaction by Anne Lesage, Chief Early Development. On September 17, 2026, an entity she controls, GrayMatters Consulting B.V., sold 20,000 shares of common stock in open-market or private transactions at a weighted average price of $38.27 per share, with individual prices ranging from $38.04 to $38.65, in connection with a cashless stock option exercise. Following these transactions, Lesage is reported as holding 73,969 shares indirectly through GrayMatters Consulting B.V. and 56,450 shares directly, and no Rule 10b5‑1 trading plan is indicated.
Modig Berndt reported disposition transactions in a Form 4 filing for PHVS. The filing lists transactions totaling 300,000 shares at a weighted average price of $35.00 per share on September 17, 2026.
Pharvaris N.V. (PHVS) has a notice of proposed sale of securities under Rule 144 filed for officer Peng Lu. The filing covers the planned sale of 100,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on September 17, 2026, following an exercise of options under a registered plan for cash.
The notice also lists prior sales of Pharvaris common stock by Peng Lu during the preceding three months, including multiple transactions in June and September 2026 with specified share amounts and total proceeds.
Pharvaris N.V. (PHVS) is the issuer for which shareholder Johannes Gerardus Christiaan Petrus Schikan has filed a notice of proposed sale of restricted or control securities under Rule 144. The filing lists a planned sale of 200,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $7,000,000.00, and discloses several prior common-share sales in the past three months.
Pharvaris N.V. (PHVS) is the issuer of common shares covered by a notice of proposed sale filed for the account of SCHOODIC MANAGEMENT under Rule 144. The notice lists plans to sell 300,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services with an aggregate market value of $10,500,000.00 based on the reported market price. The shares are described as Founder Stock originally acquired from the issuer for cash on November 26, 2015. The notice also reports prior sales during the past three months totaling 6,875 common shares by Berndt Axel Edward Modig on July 13, 2026, August 14, 2026, and September 14, 2026.
Pharvaris N.V. (PHVS) director Elisabeth E. Bjork has filed a notice of proposed sale on Form 144 covering 52,500 shares of common stock. The shares are expected to be sold through Morgan Stanley Smith Barney LLC, following a stock option exercise for cash dated September 17, 2026.
Pharvaris N.V. (PHVS) is the issuer of common shares that a shareholder affiliated with Graymatters Consulting plans to sell under Rule 144. The notice covers up to 20,000 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $765,466.00 and an intended sale date of September 17, 2026 on NASDAQ.
In the preceding three months, persons associated with the same address, including Anne Lesage and Graymatters Consulting B.V., reported several open-market sales of Pharvaris common shares, such as 30,000 shares on September 10, 2026 for $1,149,084.00 and 30,703 shares on June 30, 2026 for $1,089,637.19.